Informing informed decision making in Primary Prostate Cancer treatment selection.

The National Institute for Health and Clinical Excellence (NICE) in 2019 have just published their updated topics in the diagnosis and management of new prostate cancer (1). This is a welcome update to a much-needed area by using evidence to guide the best way to diagnose and manage a growing disease demographic. Particularly welcome is the acknowledgment of active surveillance on an equal footing with radical therapies for men with low-risk and intermediate-risk disease. NICE therefore continues to recommend" all options" for these men but not that surveillance is the preferred option.

BJU international. 2019 Sep 12 [Epub ahead of print]

Vincent J Gnanapragasam

Academic Urology Group, Department of Surgery, University of Cambridge, UK.